Press Releases
Upsher-Smith Laboratories, LLC Selects PANTHERx® Rare for the Distribution of TORPENZ™ (everolimus) Tablets
August 20, 2024
PITTSBURGH – PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce it was selected by Upsher-Smith Laboratories, LLC for the distribution of TORPENZ™ (everolimus) Tablets for...
Read More
PANTHERx® Rare Partnering with Gilead Sciences, Inc. for the Distribution of LIVDELZI®
August 16, 2024
PITTSBURGH – PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce it is partnering with Gilead Sciences, Inc. for the distribution of a novel selective peroxisome proliferator-activated...
Read More
PANTHERx® Rare Partnering with ITF Therapeutics LLC for U.S. Distribution of DUVYZAT™
July 30, 2024
PITTSBURGH – PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce it is partnering with ITF Therapeutics LLC for the U.S. distribution of DUVYZAT™ (givinostat), the first nonsteroidal...
Read More
PANTHERx® Rare Appoints Bansi Nagji as CEO; Rob Snyder appointed Executive Chair
July 25, 2024
PITTSBURGH – PANTHERx® Rare, one of the nation’s largest and fastest growing rare disease specialty pharmacies, today announced the appointment of Bansi Nagji as CEO effective August 1, 2024. In this role, Mr. Nagji will continue his existing service...
Read More
PANTHERx® Rare Pharmacy Wins Seventh Patient Choice Award
May 1, 2024
PITTSBURGH – For a seventh time, PANTHERx Rare has been recognized as the winner of the annual Independent Specialty Pharmacy Patient Choice Award™, with the announcement made at the Asembia Specialty Pharmacy Summit this week. Since 2016, the Managed...
Read More
PANTHERx® Rare Partnering with X4 Pharmaceuticals Inc. for the Distribution of XOLREMDI™ (mavorixafor), the First FDA-Approved Therapy Indicated for Use in Patients with WHIM Syndrome
April 29, 2024
PITTSBURGH – PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, today announced it was selected by X4 Pharmaceuticals, Inc. for the distribution of XOLREMDI™ (mavorixafor), recently approved by the...
Read More
No posts found